Terns Pharma Q2 net loss widens to $13.9M; cash runway into 2025

Terns Pharmaceuticals, Inc.

2023-Q2 EPS reported -$1.10

Net loss of $13.9M ($0.55 per share) vs $10.7M ($0.43) in Q2 2021.
Cash and equivalents $139.8M as of June 30, down from $166.0M at Dec 31, 2021; expected to fund operations into 2025.
R&D expenses $8.7M (up from $6.0M); G&A $5.4M (up from $4.9M).
TERN-701 Phase 1 CML trial initiated in China; TERN-601 IND-enabling on track for Phase 1 obesity trial in 2023.
TERN-501 Phase 2a DUET NASH trial initiated; top-line data expected H2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.